{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2007)
First approved in 2007
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:bavebegene tovacivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:rilimogene glafolivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:rilimogene galvacirepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:raxorulimogene belzovacirepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:mesmulogene ancovacivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:tipapkinogene sovacivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03294083: Phase 1/Phase 2 Interventional Active, not recruiting Renal Cell Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02759588: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03493945: Phase 1/Phase 2 Interventional Completed Metastatic Prostate Cancer
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE